Vimirogant
Based on 1 publication(s) in Google Scholar
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor with a Ki of 3.5 nM for binding to RORγt. VTP-43742 blocks Th17 cell differentiation and reduces IL-17A production by inhibiting RORγt-mediated transcriptional activity, thereby suppressing the RORγt/Th17/IL-17 inflammatory axis. VTP-43742 can be used for research on autoimmune diseases and inflammation-related diseases.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Vimirogant hydrochloride) that retains the same biological activity.
For research use only. We do not sell to patients.
- CAS No.: 1802706-04-2
- Formula: C27H35F3N4O3S
- Molecular Weight:552.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Vimirogant
More
Biological Activity
Description
IC50 & Target
[3]|
RORγt 3.5 nM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
21 nM
Compound: 22; VTP-43742, AGN 242428
|
Inhibition of IL-17A secretion in human PBMC cells
Inhibition of IL-17A secretion in human PBMC cells
|
[PMID: 30010338] |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Vimirogant (high dose; prophylactic administration) completely suppresses EAE clinical scores in the chronic EAE study, with a greater degree of inhibition than MM17F3; it also suppresses Th17-related markers in the spinal cord and reduces demyelination and inflammatory cell infiltration[4].
Vimirogant (30 μg/kg; p.o.; 7 days; combined with SYD 2.50 g/kg) inhibits colonic mucosal inflammatory injury more strongly than SYD alone in DSS-induced colitis mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N mice (male, 6-8 weeks old, 20 g, SPF grade)[5]
-
Dosage:30 μg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Considerably decreased M1 macrophage polarization in the colonic mucosa.
Produced milder colonic inflammatory lesions and lower sensitivity to DSS-induced colitis.
Did not alter IL-17a expression according to the article text.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1802706-04-2
-
Molecular Weight 552.65
-
Formula C27H35F3N4O3S
-
SMILES
O=C(C1=CN=C([C@H](C(C)C)N(C[C@H]2CC[C@H](C(F)(F)F)CC2)C3)C3=C1)NCC4=NC=C(S(=O)(CC)=O)C=C4
-
Synonyms
VTP-43742
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Shaoyao decoction alleviates DSS-induced colitis by inhibiting IL-17a-mediated polarization of M1 macrophages. [Abstract]2025 Jan 30;337(Pt 3):118941. PMID: 39427735
Purity & Documentation
References
[2]. Gege C, et al. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert opinion on therapeutic patents. 2017 Jan;27(1):1-8. [Content Brief]
[5]. Wang S, et al. Shaoyao decoction alleviates DSS-induced colitis by inhibiting IL-17a-mediated polarization of M1 macrophages. Journal of ethnopharmacology. 2025 Jan 30;337(Pt 3):118941. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)